Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia (SHTG): The ENTRUST Study

NCT05852431 is registered in ClinicalTrials.gov with 89bio, Inc. as lead sponsor.

NCT NCT05852431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05852431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia (SHTG): The ENTRUST Study
Lead sponsor
89bio, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 15, 2023
Completion date
April 9, 2026
Enrollment
369 (actual)
Sites
177

Conditions

As the registry lists them; a condition with its own page is linked.

severe hypertriglyceridemia